PE20071138A1 - Derivados de pirimidina como inhibidores de quinasas - Google Patents

Derivados de pirimidina como inhibidores de quinasas

Info

Publication number
PE20071138A1
PE20071138A1 PE2006001661A PE2006001661A PE20071138A1 PE 20071138 A1 PE20071138 A1 PE 20071138A1 PE 2006001661 A PE2006001661 A PE 2006001661A PE 2006001661 A PE2006001661 A PE 2006001661A PE 20071138 A1 PE20071138 A1 PE 20071138A1
Authority
PE
Peru
Prior art keywords
halogen
pyrimidine derivatives
kinase inhibitors
epiazan
ilamino
Prior art date
Application number
PE2006001661A
Other languages
English (en)
Inventor
Joel Thomas Arcari
Samit Kumar Bhattacharya
Arthur Douglas Brosius
Michael Joseph Luzzio
Kendra Louise Nelson
Gonghua Pan
Southers
Donn Gregory Wishka
Jun Xiao
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20071138A1 publication Critical patent/PE20071138A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE PIRIMIDINA DE FORMULA (I), EN DONDE Ar ES DE FORMULA (III), K ES C(R1) O N; M ES C(H) O N; Q ES C(D) O N; D ES H, HALOGENO, -NO2, -CN, ENTRE OTROS; R1 Y R2 SON INDEPENDIENTEMENTE H, HALOGENO, HIDROXI, -CF3, ENTRE OTROS; O R2 ES -N(RE)-(CRFRG)n-RH-; R13 ES H, ALQUILO (C1-C6), ENTRE OTROS; A ES CICLOALQUILO(C3-C10), -ARILO(C6-C10), ENTRE OTROS; Z1 Y Z2 SON -C-, -N-, -CR7-; Y1 E Y2 SON -N-, -CR7-; L1 Y L2 SON C(O), S, O, ENTRE OTROS; q ES DE 0 A 3; X Y W SON INDEPENDIENTEMENTE C(O), S, S(O), ENTRE OTROS; R7 ES H, HALOGENO, NO2, ENTRE OTROS; m ES DE 1 A 4; p ES DE 1 A 4. SON SELECCIONADOS: 1-[6-(4-CICLOBUTILAMINO-5-TRIFLUOROMETIL-PIRIDIN-2-ILAMINO)-(1S,4R)-1,2,3,4-TETRAHIDRO-1,4-EPIAZAN-NAFTALEN-9-IL]-2-HIDROXI-ETANONA, 2-AMINO-1-[6-(4-CICLOBUTILAMINO-5-TRIFLUOROMETIL-PIRIMIDIN-2-ILAMINO)-(1S,4R)-1,2,3,4-TETRAHIDRO-1,4-EPIAZAN-NAFTALEN-9-IL]-ETANONA, ENTRE OTROS. SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE QUINASA Y DE LAS TIROSINA QUINASAS NO RECEPTORAS Y SON UTILES EN EL TRATAMIENTO DEL CRECIMIENTO CELULAR ANORMAL TAL COMO EL CANCER
PE2006001661A 2005-12-21 2006-12-20 Derivados de pirimidina como inhibidores de quinasas PE20071138A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75270805P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
PE20071138A1 true PE20071138A1 (es) 2007-12-29

Family

ID=38038639

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001661A PE20071138A1 (es) 2005-12-21 2006-12-20 Derivados de pirimidina como inhibidores de quinasas

Country Status (30)

Country Link
US (1) US7820648B2 (es)
EP (1) EP1966207A2 (es)
JP (1) JP4332590B2 (es)
KR (1) KR101060051B1 (es)
CN (1) CN101346380B (es)
AP (1) AP2008004488A0 (es)
AR (1) AR058399A1 (es)
AU (1) AU2006327871A1 (es)
BR (1) BRPI0620324A2 (es)
CA (1) CA2634646C (es)
CR (1) CR10095A (es)
DO (1) DOP2006000289A (es)
EA (1) EA014551B1 (es)
EC (1) ECSP088563A (es)
GT (1) GT200600517A (es)
HN (1) HN2006042221A (es)
IL (1) IL191555A0 (es)
MA (1) MA30075B1 (es)
ME (1) MEP0908A (es)
NL (1) NL2000375C2 (es)
NO (1) NO20082338L (es)
PE (1) PE20071138A1 (es)
RS (1) RS20080272A (es)
SV (1) SV2008002969A (es)
TN (1) TNSN08270A1 (es)
TW (1) TW200736258A (es)
UA (1) UA89123C2 (es)
UY (1) UY30051A1 (es)
WO (1) WO2007072158A2 (es)
ZA (1) ZA200804488B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
EP2041132A2 (en) * 2006-07-06 2009-04-01 Boehringer Ingelheim International GmbH New compounds
WO2008051547A1 (en) * 2006-10-23 2008-05-02 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
DK2146779T3 (en) 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
NZ582485A (en) 2007-07-17 2012-05-25 Rigel Pharmaceuticals Inc Cyclic amine substituted pyrimidinediamines as pkc inhibitors
JP2011505407A (ja) * 2007-12-03 2011-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 過剰な又は異常な細胞増殖を特徴とする疾患を治療するためのジアミノピリジン
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
US8372974B2 (en) * 2008-03-20 2013-02-12 Boehringer Ingelheim International Gmbh Regioselective preparation of substituted pyrimidines
BRPI0914927B8 (pt) 2008-06-17 2021-05-25 Astrazeneca Ab composto, composição farmacêutica e uso de um composto
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
JP5607241B2 (ja) 2010-05-21 2014-10-15 ケミリア・エービー 新規ピリミジン誘導体
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
AU2012230229A1 (en) 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
CA2858420A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
CN104169272A (zh) 2011-12-23 2014-11-26 赛尔佐姆有限公司 作为激酶抑制剂的嘧啶-2,4-二胺衍生物
CN103655577A (zh) * 2012-09-20 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103664957A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN105130907B (zh) * 2015-07-29 2018-10-16 沈阳药科大学 嘧啶类化合物及其用途
EP3484528B1 (en) 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Tau pet imaging ligands
WO2020023851A1 (en) * 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
EP4274829A1 (en) * 2021-01-07 2023-11-15 Ontario Institute for Cancer Research (OICR) Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
JP2006508997A (ja) 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
JP2006515014A (ja) 2003-01-30 2006-05-18 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド ＰＫＣ−θのインヒビターとして有用な２，４−ジアミノピリミジン誘導体
JP4099212B2 (ja) * 2004-05-14 2008-06-11 ファイザー・プロダクツ・インク 異常な細胞増殖を処置するためのピリミジン誘導体
EP1758887A1 (en) * 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
AP2008004488A0 (en) 2008-06-30
UY30051A1 (es) 2007-07-31
SV2008002969A (es) 2010-08-17
EA200801287A1 (ru) 2008-10-30
WO2007072158A3 (en) 2007-12-27
AR058399A1 (es) 2008-01-30
AU2006327871A1 (en) 2007-06-28
CR10095A (es) 2008-07-17
MA30075B1 (fr) 2008-12-01
WO2007072158A2 (en) 2007-06-28
IL191555A0 (en) 2008-12-29
NL2000375A1 (nl) 2007-06-25
GT200600517A (es) 2007-09-13
BRPI0620324A2 (pt) 2011-11-08
US7820648B2 (en) 2010-10-26
HN2006042221A (es) 2010-01-18
NL2000375C2 (nl) 2008-01-03
KR20080077026A (ko) 2008-08-20
TNSN08270A1 (fr) 2009-10-30
TW200736258A (en) 2007-10-01
US20080234303A1 (en) 2008-09-25
CA2634646C (en) 2012-04-10
CN101346380B (zh) 2012-02-29
NO20082338L (no) 2008-06-25
UA89123C2 (ru) 2009-12-25
KR101060051B1 (ko) 2011-08-29
ZA200804488B (en) 2009-05-27
EA014551B1 (ru) 2010-12-30
CN101346380A (zh) 2009-01-14
MEP0908A (xx) 2010-02-10
JP4332590B2 (ja) 2009-09-16
ECSP088563A (es) 2008-07-30
EP1966207A2 (en) 2008-09-10
JP2009520807A (ja) 2009-05-28
WO2007072158A8 (en) 2008-08-14
RS20080272A (en) 2009-07-15
CA2634646A1 (en) 2007-06-28
DOP2006000289A (es) 2007-07-31

Similar Documents

Publication Publication Date Title
PE20071138A1 (es) Derivados de pirimidina como inhibidores de quinasas
PE20060957A1 (es) Compuestos pirazolopiridinas su preparacion y composiciones farmaceuticas
AR112833A2 (es) Compuestos pirazolo[1,5-a]pirimidina sustituida como inhibidores de trk cinasa
PE20190475A1 (es) Inhibidores de cdk2/4/6
ATE474835T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
PE20120795A1 (es) Derivado de aminopirazol
PE20061073A1 (es) Compuestos derivados de piperidinilamida como agentes inhibidores de quinasas
NI201000050A (es) Derivados de pirrolo [2, 3-d] pirimidina como inhibidores de proteínas quinasas b.
TN2009000215A1 (en) Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
MX2008005818A (es) Aminopirimidinas utiles como inhibidores de cinasa.
PE20070517A1 (es) Derivados de imidazol como agentes inhibidores de la sintasa de aldosterona y aromatasa
NO20072795L (no) Pyrazol [1,5-a]pyrimidiner som er nyttige som inhibitorer av proteinkinaser
CO6630187A2 (es) 5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak
PE20120506A1 (es) Derivados de pirazolopiridina como inhibidores de quinasas
PE20090902A1 (es) Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos
UY29301A1 (es) Derivados amida
EA200800726A1 (ru) Введение ингибиторов дипептидилпептидазы
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
PE20080948A1 (es) Derivados de imidazol como moduladores de la senda de hedgehog
EA201270339A1 (ru) Замещенные производные ксантина
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2009004771A (es) Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed